Get started
Author

Bassam Francis Matti

Observed names: Bassam F Matti, Bassam F. Matti, Bassam F. Mattii, Bassam Francis, Bassam Francis Metti, Bassam Matti
ORCID: 0009-0009-6981-7426
Observed ORCID: 0009-0009-6981-7426
OpenAlex ID: A5005603116
Targeting BTK in B Cell Malignancies: From Mode of Action to Resistance Mechanisms
2024 · Samir Mouhssine, Nawar Maher, et al. · International Journal of Molecular Sciences · 47
PDF
Treatment Refractoriness in Chronic Lymphocytic Leukemia: Old and New Molecular Biomarkers
2023 · Nawar Maher, Samir Mouhssine, et al. · International Journal of Molecular Sciences · 26
PDF
Prospective single-center study of chronic myeloid leukemia in chronic phase: switching from branded imatinib to a copy drug and back
2014 · Alaa Fadhil Alwan, Bassam F. Matti, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 26
Epidemiology, Treatment Trends, and Outcomes of Multiple Myeloma in the Middle East and Africa: A Systematic Review
2024 · Mervat Mattar, Ali Bazarbachi, et al. · Clinical Hematology International · 23
PDF
Molecular Mechanisms in the Transformation from Indolent to Aggressive B Cell Malignancies
2025 · Nawar Maher, Samir Mouhssine, et al. · Cancers · 22
Evaluation of the Safety of Imatinib Mesylate in 200 Iraqi Patients with Chronic Myeloid Leukemia in the Chronic Phase: Single-Center Study
2013 · Bassam Francis Matti, Alaadin Sahham Naji, et al. · Turkish Journal of Hematology · 15
PDF
Cytogenetic Response in Chronic Myeloid Leukaemia Patients Treated with Imatinib Mesylate Homolog-Drugs: 6 Year’s Transitional Study
2014 · Najmaddin Khoshnaw, Bassam Francis, et al. · Journal of Cancer Therapy · 11
PDF
The Efficacy of Fludarabine, High Dose Cytosine Arabinoside with Granulocyte Colony Stimulating Factor (FLAG) Protocol as Salvage Therapy for Refractory/Relapsed Acute Leukemias in Adult Iraqi Patients
2013 · Alaa Fadhil Alwan, Bassam Francis Matti, et al. · Indian Journal of Hematology and Blood Transfusion · 8
PDF
role of miRNA -150 between different BCR-ABL p210 transcript levels and between different levels of imatinib optimal response in CML patients
2023 · Kawthar Ali Radhi, Bassam Francis Matti, et al. · Al-Mustansiriyah Journal of Sciences · 7
PDF
Do We Need Local Guidelines for the Diagnosis and Management of Immune Thrombocytopenia in Iraq?
2023 · Ahmed Mjali, Bassam Francis Matti, et al. · Journal of Applied Hematology · 6
Assessment of regulatory T cells (Tregs) and Foxp3 methylation level in chronic myeloid leukemia patients on tyrosine kinase inhibitor therapy
2022 · Shahla’a Fadhil Sabir, Bassam Francis Matti, et al. · Immunogenetics · 6
Assessment of Interleukin 1β Serum Level in Different Responder Groups and Stages of Chronic Myeloid Leukemia Patients on Imatinb Mesylate Therapy
2014 · Bassam Francis Matti, Maysoon Ali Saleem, et al. · Indian Journal of Hematology and Blood Transfusion · 6
PDF
Molecular Screening for T315I and F317L Resistance Mutations in Iraqi Chronic Myeloid Leukemia Non-Responders Patients to Imatinib
2013 · Maysaa Abdul Razzaq Dhahi, Bassam F. Matti, et al. · Cancer and Clinical Oncology · 6
PDF
Molecular Pathogenesis and Targeted Treatment of Richter Transformation
2026 · Nawar Maher, Amir Karami, et al. · Biomedicines · 4
PDF
Treatment Outcomes of Nilotinib as Second Line Therapy for Chronic Myeloid Leukemia Patients in Karbala Province of Iraq
2022 · Ahmed Mjali, Mustafa Majeed Obaid, et al. · Asian Pacific Journal of Cancer Care · 4
PDF
Neopterin and Interferon-gamma as Immune Response Markers in Betathalassemia Major Patients
2018 · Shahad F Obeid, Sanad B Al-a'araji, et al. · Asian Journal of Pharmaceutical and Clinical Research · 4
PDF
Evaluation of Electrolytes Disturbances in Iraqi Chronic Myeloid Leukemia Patients treated with Nilotinib with Monitoring of Response by FISH Study
2015 · Bushra F. Hasan, Bassam F. Matti, et al. · Baghdad Science Journal · 4
PDF
CD40 Gene Variants and Disease Susceptibility: A Comprehensive Review of Associations with Immune-Mediated Inflammatory Diseases, Cancer, and Infectious Diseases
2025 · Aisha Muthanna Shanshal, Samer Imad Mohammed, et al. · Al-Rafidain Journal of Medical Sciences · 3
PDF
Illness Perceptions and Response to Treatment with Romiplostim in Iraqi Patients with Refractory Immune Thrombocytopenia Purpura: A Cross-Sectional Study
2025 · Aisha Muthanna Shanshal, Samer Imad Mohammed, et al. · Al-Rafidain Journal of Medical Sciences · 2
PDF
Aberrant CD7 antigen expression as a prognostic factor for remission achievement in adult de novo acute myeloid leukemia patients treated with 3 + 7 regimen
2025 · Duha Muhanad Bayram, Fadhel M. Lafta, et al. · Iraqi Journal of Hematology · 2
Impact of IDH Mutations on DNA Methylation of Acute Myeloid Leukemia Related Genes: A Review Article
2024 · Duha M. Bayram, Fadhel M. Lafta, et al. · Journal of the Faculty of Medicine Baghdad · 2
PDF
The Role of Immune Check Point Gene Expression of Pd-1 and Tim-3 in Patients with Acute Myeloid Leukemia
2024 · Sara Mohammed Oudah, Israa Hussein Hamzah, et al. · Al-Mustansiriyah Journal of Sciences · 2
PDF
Treatment outcome of the tyrosine kinase inhibitor (bosutinib) in previously treated chronic myeloid leukemia patients (sample of Iraqi patients)
2024 · Anfal Mumtaz Ahmed, Bassam Francis Matti · Iraqi Journal of Hematology · 2
Evaluation of HOXA5 methylation–gene expression in response to Imatinib mesylate treatment in chronic myeloid leukemia
2023 · Noor Hashim Ismail, Ismail Abdulridha Abdulhassan, et al. · Biomedicine · 2
PDF
The role of miRNA -181C between different BCR-ABL p210 transcript levels and between different levels of imatinib optimal response in CML patients
2022 · Kawthar Ali Radhi, Israa Hussein Hamzah, et al. · Human Gene · 2
Works count: 55
Citation count: 253
H-index: 8
I10-index: 7
Year
Topic
Type